INTRODUCTION

Today, the rate of allogeneic hematopoietic stem cell transplantation (allo-HSCT) continues to increase. About 50,000-60,000 transplantations are performed annually, worldwide.\(^1\) Graft-versus-host disease (GVHD) is a major complication and therapeutic challenge of allo-HSCT with the prevalence of 20%-60%.\(^2,3\) During the progression of GVHD, donor driven T cells can be primed against
recipient antigens and cause severe morbidity and mortality. There are two types of GVHD, including acute (aGVHD) and chronic (cGVHD). The median time of aGVHD and cGVHD is typically 21-25 days and 4.5 months, respectively, with the incidence of 30%-50% and 30%-70%, in the order given. There are many risk factors affecting the development of GVHD in HSCT patients, including type of the graft, donor-recipient relationship, HLA and sex matching, recipient age, intensity of conditioning and prophylaxis regimens. The previous studies identified that HSCT process alters serum uric acid (UA) levels in allo-HSCT. During HSCT process, conditioning regimen leads to promotion of endogenous danger signaling such as heat shock proteins and UA. Moreover, radio/chemotherapy induces UA crystallization and deposition by increasing serum UA which can result in neutrophil migration into tissues and intensifying the inflammation. UA from damaged cells releases into extracellular fluid and induces antigen-presenting cells (APCs) for activating the immune response. In fact, UA is a danger-associated molecular pattern (DAMP) capable of inducing T cells to release IL-1B through the activation of the NOD-like receptor protein (NLRP). Regarding the previous studies indicating the UA-mediated activation of host APC and T-cell response, the elevated UA levels may play a critical role in the immune activation and inflammation. There are several studies about the relationship between UA levels and the incidence of GVHD and overall survival in allo-HSCT patients with controversial findings. Formerly, UA-decreasing drugs such as uricase or allopurinol in allo-HSCT patients have been shown to inhibit cytotoxic T lymphocytes activity and reduce the development of aGVHD. On the other hand, a recent study found a negative association between UA levels and GVHD showing the need for more clarification. Therefore, in this study, we aimed to evaluate the relationship between UA levels as a sensitive parameter and GVHD incidence as well as overall survival in patients who underwent allo-HSCT.

2 | METHODS AND PATIENTS

2.1 | Patient’s characteristics

A total of 201 patients with hematological disorders who were admitted for allogeneic transplantation at Taleghani hospital, Tehran, Iran, between 2008 and 2018 were considered for retrospective data analysis. All patients were categorized based on their diagnosed disease, including acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), aplastic and Fanconi anemia (AA, AF), Hodgkin disease (HD), non-Hodgkin lymphoma (NHL), and others. These patients gave the informed consent that their data were used for scientific analysis, and the study was approved by the Ethics Committee of the Shahid Beheshti University of Medical Sciences (Tehran, Iran). The samples of bone marrow were used for disease diagnosis by standard techniques such as karyotyping, hemograms, and cell surface marker detection. High-dose chemotherapy-based myeloablative conditioning (MAC) regimens were administered for allo-HSCT including ALL, AML, and CML received MAC-1 regimen (busulfan [BU; Otuska]: 3.2 mg/kg/d from day −7 to −4 and cyclophosphamide [CY; Sandoz]: 60 mg/kg/d on day −3 and −2) or MAC-2 (BU 3.2 mg/kg/d from day −6 to −3 and fludarabine [Flu; Genzyme] 30 mg/m² of body area/d from day −6 to −3) or MAC-3 which is MAC-2 plus antithymocyte globulin (ATG; Genzyme) (1.5 mg/kg/d on days −3, −2, and −1). Aplastic and Fanconi anemia patients received CY 60 mg/kg/d on day −3 and −2 with ATG (1.5 mg/kg/d on days −3, −2, and −1). Patients with HD and NHL received Reduced Intensity Conditioning regimen (RIC) consists of Flu 30 mg/m² of body area for 5 days, CCNU (Lomustine, Bristol Myers) 100 mg/m² for 2 days and Melphalan (Alkeran; GlaxoSmithKline) 40 mg/m² for 1 day. GVHD prophylaxis was methotrexate (MTX; Sandoz) plus cyclosporine A (CSA; Sandoz) with or without ATG. The course of methotrexate therapy was 10 mg/m² of body surface on days +1, +3, +6, and +11 and for cyclosporine was 5 mg/kg/d in two divided doses on day −5. The level of cyclosporine was maintained between 200 and 300 ng/mL. Also, the ATG was given as 1.5 mg/kg/d on days −3, −2, and −1.

2.2 | HSCT process and GVHD evaluation

The peripheral blood stem cells (PBSC) were mobilized after 4 days of 10 mg/kg G-CSF (filgrastim; Amgen) administered in HSCT donor. Apheresis was 250 minutes depending on the volume and speed of blood flow of PBSC donor. Cell viability in apheresis product was assessed using the trypan blue staining (Sigma-Aldrich; Merck Millipore) and enumeration on a Neubauer chamber with light microscopy. Also, the counts of CD34+ (PE-conjugated, EXBIO) cells and CD3+ (FITC-conjugated; Beckman Coulter) cells were evaluated by flow cytometry (Attune NxT; Life Technologies).

The standard clinical signs such as rash, diarrhea, and liver function abnormalities associated with biopsy and histopathological criteria in involved organ were main manifestations for diagnosis of GVHD according to the GVHD criteria provided by National Institute of Health.

2.3 | Laboratory test

Serum UA levels were measured from day −7 until day +14. Peripheral blood samples were collected, and UA levels in serum samples were evaluated using an ADVIA 1800 clinical chemistry analyzer (Toshiba).

2.4 | Statistical analysis

Data were expressed as means ± standard deviation (SD) or frequency (%). The main purpose of this study was to identify the effects of serum UA on the incidence of GVHD and the overall survival with the adjusted effect of other risk factors. The logistic regression was employed when the outcome variable was GVHD. The odds
3 of 9

ratios, 75 and 90% confidence interval (CI), were calculated accordingly. When the outcome was the overall survival, we conducted a Cox regression analysis. The hazard ratios, 75 and the 90% CI were evaluated as well. The median of serum UA in each disease category as well as the correlation of UA level with the overall survival was determined.

The threshold for serum UA level in three different periods of time including 1 week before transplant, 1 and 2 weeks after transplant was determined using both the receiver operating characteristic (ROC) curves and median. The sensitivity, specificity, and the area under curve (AUCs) were also assessed in ROC curves analysis. Finally, due to the importance of the week before transplantation, the median of UA level in the time period between day −7 to the transplantation day was selected as the cutoff and utilized in the univariable and multivariable analysis. The survival curve was drawn based on the median of serum UA. The P-value <.25 in univariable analysis and P-value <.1 in multivariable was considered as significant. All analyses were conducted through the SPSS version 19.0 (SPSS Inc).

3 | RESULTS

3.1 | Descriptive statistics and UA cutoff determination

The descriptive statistics is shown in Table 1. The analysis was performed on 201 patients with hematological disorders with a mean age of 32.53 years. The most diagnosed disease was AML comprising 48.8% of all patients. About half of the patients 103 (51.2%) received MAC1 and approximately more than 74% of the recorded conditioning regimens were MAC1 and MAC2. The median of serum UA levels in the period of 1 week before the transplantation was 3.4 mg/dL which is selected as cutoff for the statistical analysis. Almost 45% of the patients had UA levels lower than 3.4 mg/dL.

3.2 | Predictive values of the serum uric acid level before and after HSCT for GVHD

Beside the median of serum UA levels during the week before transplantation as the main cutoff point for UA in this study, the ROC curve was also drawn to determine a cutoff and evaluate the predictive values of serum UA level before and after transplant for GVHD. As shown in Table 2, the AUC, sensitivity, and specificity for the meantime of 1 week before transplant for GVHD were 59% (CI: 0.50-0.67), 76%, and 39%, respectively with a cutoff value of 2.98 mg/dL. Therefore, it can be suggested that serum UA level of 7 days before transplant can be used as a relatively poor predictive of GVHD since the AUC is close to 60%. The cutoff value of UA level in 1 week after transplantation for GVHD was 3.91 mg/dL with the AUC of 47% (CI: 0.37-0.56), sensitivity of 29%, and specificity of 82%. So, it is suggested that the serum UA level for the meantime of the 7 days after transplant cannot be a predictive of GVHD, since the AUC is below 50%. For the meantime of 2 weeks after transplant for GVHD, the AUC, sensitivity, and specificity were 54% (CI: 0.44-0.63), 45%, and 67%, one by one with a cutoff value of 4.23 mg/dL. Thus, we can say that the serum UA level for the meantime of 2 weeks after transplant may be a poor predictive of GVHD, since the AUC is close to 60.

### Table 1: Descriptive Statistics

| Variables        | Frequency (Mean ± SD) |
|------------------|-----------------------|
| Recipient age    | 32.53 ± 10.83         |
| Missing          | 8 (4)                 |
| Donor age        | 31.81 ± 11.26         |
| Missing          | 64 (31.8)             |
| DP gender        |                       |
| M-M              | 56 (27.9)             |
| M-F              | 59 (29.4)             |
| F-F              | 31 (15.4)             |
| F-M              | 48 (23.9)             |
| Missing          | 7 (3.5)               |
| Diagnosed disease|                       |
| NHL              | 13 (6.5)              |
| HD               | 12 (6.0)              |
| AML              | 98 (48.8)             |
| ALL              | 51 (25.4)             |
| AA               | 8 (4)                 |
| Other            | 6 (3)                 |
| Missing          | 13 (6.5)              |
| Recipient CMV IgG|                       |
| Positive         | 84 (41.8)             |
| Negative         | 12 (6.0)              |
| Missing          | 105 (52.2)            |
| Conditioning regimen|                   |
| MAC1             | 103 (51.2)            |
| MAC2             | 46 (22.9)             |
| MAC3             | 16 (8.0)              |
| RIC              | 21 (10.4)             |
| AA-AF            | 7 (3.5)               |
| Missing          | 8 (4.0)               |
| Prophylaxis regimen|                   |
| CSA + MTX        | 124 (61.7)            |
| CSA + MTX+ATG    | 20 (10)               |
| Unclassified     | 57 (28.4)             |
| Uric acid        |                       |
| Higher than 3.4  | 85 (42.3)             |
| Lower than 3.4   | 90 (44.8)             |
| Missing          | 26 (12.9)             |
Predictive values of the serum uric acid level before and after HSCT for overall survival

In order to determine the predictive values of serum UA level before and after transplant for overall survival, we performed ROC analyses. The results are indicated in Table 3. The AUC, sensitivity, and specificity for the meantime of 1 week before transplant for OS were 53% (CI: 0.42-0.64), 45%, and 69%, respectively, with cutoff value of 3.79 mg/dL. For the meantime of 1 week post-transplant, the AUC, sensitivity, and specificity were 50% (CI: 0.39-0.62), 37%, and 89%, successively with a cutoff value of 4.10 mg/dL. The cutoff value of serum UA level for 2 weeks post-transplant was 4.66 mg/dL with the AUC of 53% (CI: 0.42-0.64), sensitivity of 42%, and specificity of 76%. All of these AUCs were around 50%. Hence, none of them can be strong predictive of OS.

Association of high serum UA and other risk factors with GVHD

We conducted a univariable and multivariable logistic regression to identify the pre-transplant risk factors for GVHD. The results are illustrated in Table 4. As we can see in the univariable analysis, the cutoff value of serum UA level at 3.4 mg/dL has a significant effect on the occurrence of GVHD. The odds of incidence, consecutively compared to blood group O (CI: 0.44-0.91); P-value = .15). The survival curve illustrated that the overall survival of patients with the median serum UA levels higher than 3.4 mg/dL was better than the patients whose median UA levels were lower than 3.4 mg/dL (Figure 1). The other factors such as diagnosed disease, CMV, and conditioning regimen did not have any significance effect on the incidence of GVHD. The results of the multivariable analysis were significant for blood group A which revealed that the odds of incidence in patients with blood group A was half the patients with blood group O (CI: 0.28-0.95), P-value = .07).

Association of high serum UA and other risk factors with overall survival

We applied a Cox proportional hazards model in order to determine the significant risk factors on the survival of the patients. As it is illustrated in Table 5, the hazard of death decreased in older patients by 2% (CI: 0.96-0.99); P-value = .20). The diagnosed disease was a risk factor which suggested a significant effect on the hazard of death (P-value = .03). The hazard of death in patients with AML was almost half of those classified in subgroup “HD” (CI: 0.23-0.80), P-value = .12).

The conditioning regimen was among the influential factors illustrating that in MAC2 regimen, the hazard of death was 2.63 times greater than the RIC regimen (CI: 1.37-5.02), P-value = .08). Prophylaxis regimen of CSA + MTX+ATG increased the death hazard up to 2.14 times greater than the regimen of CSA + MTX (CI: 1.33-3.41), P-value = .06). The patients with serum UA higher than 3.4 mg/dL had the hazard of death 35% lower than patients with UA lower than 3.4 mg/dL (CI:0.47-0.92), P-value = .15). The survival curve illustrated that the overall survival of patients with the median serum UA levels higher than 3.4 mg/dL was better than the patients whose median UA levels were lower than 3.4 mg/dL (Figure 1). The other factors in the model were not associated with the survival of the patients. Besides, none of the variables were found to be significant in the adjusted multivariable model demonstrated in Table 5. Table 6 indicates the median of serum UA and hyperuricemia in each disease type, separately. The correlation of serum UA level with OS was also conducted. As shown, the serum UA level only in AML patients had a significant correlation with the overall survival in which the increased UA level resulted in poor survival of the patients (P-value: .03).

Discussion

The radio/chemotherapy, along with the conditioning regimen before the HSCT, cause massive cell death in all organs of the patients. Dying cells release a variety of molecules which is called DAMPs or danger signals including extracellular adenosine triphosphate, UA, high mobility group box-1 protein, etc.12,17,18 UA is of the most critical danger signals activates the innate and adaptive immunity and provokes the inflammation.12 Through NLRP3 inflammasome-mediated production of IL1, UA affects the T-cell responses, which are the most responses in GVHD. Studies have reported the role of NLRP3 inflammasome, IL1, and DAMPs in the pathogenesis of GVHD.12,19,20
The accessibility and ease of measurement together with its role in the inflammatory conditions, such as HSCT, make the serum UA as an attractive biomarker in researches to predict the GVHD. However, the role of UA in inflammation is still controversial. In allogeneic responses such as kidney transplantation, high levels of UA are associated with both cellular and humoral immune activation leading to graft rejection or poor graft survival. In HSCT, also, UA is introduced as a sensitive biomarker to distinguish the graft failure from poor graft function, but its predictive role in GVHD is a matter of debate. Preclinical and phase I clinical studies have reported that UA-decreasing drugs, including uricase and allopurinol, can diminish the GVHD incidence and alleviate its severity. These studies concluded that high UA level is a risk factor for GVHD and should be decreased before HSCT to control the GVHD. Albeit, these reports were about the association of UA-decreasing drugs with GVHD. Moreover, several studies implied the association of low UA levels and inflammatory and degenerative diseases.

The purpose of this study was to identify the effects of serum UA on the incidence of GVHD and the overall survival with the adjusted effect of other risk factors. To achieve this goal, serum UA levels of 201 patients with hematological disorders were measured from 1 week before the allo-HSCT until 2 weeks after transplantation. The threshold for serum UA level in three different periods, including 1 week before transplant, 1 and 2 weeks after transplant was determined using ROC curves. As it is illustrated in the results, the AUC of the cutoff determined by ROC for prediction of both GVHD incidence and overall survival in all three periods was lower.
than 60% which means these cutoffs have low capacity to predict the outcomes. Moreover, the sensitivity and specificity of the cutoffs were low. These results show that the thresholds achieved by ROC curve are not a reliable cutoff to predict the HSCT outcome.

The other method that is used to determine the cutoff for serum UA in our patients was median. The median of serum UA levels in the period of 1 week before the transplantation was 3.4 mg/dL, which was selected as a cutoff for the statistical analysis. Generally, the cutoff point for hyperuricemia is 6.7 mg/dL at which the crystallization of UA begins.27 Our determined cutoff was median and was not based on the crystallization point. The reason for choosing 1 week before HSCT to define a cutoff is that the UA levels in this period are critical in determining the fate of HSCT. Previous reports pointed out that the pre-transplant UA decrease can affect the GVHD.14,18,19

Our univariable analysis showed that the cutoff value of serum UA level at 3.4 mg/dL has a significant effect on the occurrence of GVHD in a way that GVHD incidence in patients with UA higher than 3.4 mg/L was 37% lower than patients with the UA below the cutoff. However, the multivariable analysis showed no significant association between serum UA levels and GVHD. This finding contradicts with some previous reports which claimed that the higher serum UA is associated with GVHD incidence and its severity,22,23 albeit it is in parallel with the report of Ostendorf et al14 that low UA levels in both univariable and multivariable analyses significantly associated with grade II-IV acute GVHD.

The probable explanation provided by Ostendorf and his colleagues for the negative association between UA levels and GVHD was the reduced antioxidative capacity in case of hypouricemia.14 This explanation raised from the evidence suggests that UA is the

| Variables                  | Univariable Hazard ratio (75% CI) | P-value | Multivariable Adjusted hazard ratio (90% CI) | P-value |
|----------------------------|-----------------------------------|---------|---------------------------------------------|---------|
| Recipient age              | 0.98 (0.96-0.99)                  | .20*    | 0.98 (0.96-1.01)                            | .46     |
| Diagnosed disease          |                                   |         |                                             |         |
| NHL                        | 0.41 (0.15-1.12)                  | .31     | 0.81 (0.64-1.34)                            | .34     |
| AML                        | 0.43 (0.23-0.80)                  | .12*    | 0.75 (0.41-1.34)                            | .42     |
| ALL                        | 0.54 (0.96-4.68)                  | .28     | 0.59 (0.81-1.98)                            | .58     |
| Aplastic anemia            | 2.13 (0.96-4.68)                  | .38     | 1.78 (0.91-2.83)                            | .45     |
| Other                      | 0.94 (0.39-2.30)                  | .94     | 0.67 (0.88-2.45)                            | .63     |
| HD (RL)                    | -                                 | -       | -                                           | -       |
| Recipient CMV              | -                                 | -       |                                             | -       |
| Positive                   | 0.79 (0.47-1.31)                  | .59     |                                             |         |
| Negative(RL)               | -                                 | -       |                                             | -       |
| Conditioning regimen       |                                   |         |                                             |         |
| MAC1                       | 1.57 (0.85-2.90)                  | .39     | 2.45 (0.45-2.64)                            | .25     |
| MAC2                       | 2.63 (1.37-5.02)                  | .08*    | 1.56 (0.78-3.11)                            | .28     |
| MAC3                       | 1.07 (0.39-2.91)                  | .93     | 3.35 (0.93-1.81)                            | .29     |
| AA-AF                      | 2.24 (0.82-6.11)                  | .35     | 2.21 (0.99-5.45)                            | .31     |
| RIC (RL)                   | -                                 | -       | -                                           | -       |
| Blood group                |                                   | .64     |                                             |         |
| A                          | 0.96 (0.64-1.45)                  | .92     |                                             |         |
| B                          | 1.36 (0.87-2.13)                  | .41     |                                             |         |
| AB                         | 1.50 (0.91-2.46)                  | .34     |                                             |         |
| O(RL)                      | -                                 | -       | -                                           | -       |
| Prophylaxis regimen        |                                   | .48     |                                             |         |
| CSA + MTX+ATG              | 2.14 (1.33-3.41)                  | .06*    |                                             |         |
| CSA + MTX (RL)             | -                                 | -       | -                                           | -       |
| Uric acid                  |                                   | .15*    |                                             | .41     |
| >3.4                       | 0.65 (0.47-0.92)                  | .15*    | 0.72 (0.38-1.38)                            | .41     |
| ≤3.4 (RL)                  | -                                 | -       | -                                           | -       |

Abbreviation: RL, Reference level.
*Significant at 0.25.
major natural antioxidant in the periphery, and reduced antioxidative capacity is associated with GVHD.\textsuperscript{28-31} Except for the serum UA levels and blood group, other factors such as diagnosed disease, CMV, and conditioning regimen did not have any significant effect on the incidence of GVHD. The blood group A and B also significantly increased the GVHD incidence, compared to blood group O, which might be due to the ABO antibodies and blood group incompatibility in some patients.

In accordance with the results of GVHD, it is indicated that the lower serum UA levels are associated with a higher risk of death and inferior overall survival. It is found that patients with serum UA higher than 3.4 mg/dL had 35% lower hazard of death compared to patients with UA lower than 3.4 mg/dL. Despite the significant association of low UA levels with the GVHD incidence, Ostendorf et al\textsuperscript{14} reported no significant association reported between low UA levels and OS.

Of note, including the ATG to the prophylaxis regimen, increased the hazard of death up to 2.14 times greater, compared to the regimen without ATG. It should be noted that all significant results in overall survival came from univariable analysis and multivariable analysis showed no significant effect which indicates that each prognostic factor in the presence of other factors has no significant role in the prediction of OS.

Moreover, in our univariable analysis, the patients diagnosed with AML showed better OS among other diseases. Intriguingly, hyperuricemia was reported in one-third of hematological malignancies such as AML and demonstrated to be associated with poor prognosis and poor survival in AML.\textsuperscript{32-34} To clarify the role of UA levels on

**TABLE 6** Correlation of uric acid with overall survival based on diseases

| Diagnosis          | Median of UA (mg/dL) | Hyperuricemia a (%) | Correlation of UA with OS |
|--------------------|----------------------|---------------------|---------------------------|
|                    |                      |                     | P-value | CC          |
| NHL                | 2.9                  | 30.7                | .53     | -.24        |
| HD                 | 4                    | 50                  | .08     | -.53        |
| AML                | 3.3                  | 44.8                | .03*    | -.22        |
| ALL                | 3.2                  | 41.1                | .06     | -.41        |
| Aplastic anemia    | 2.8                  | 16.6                | .60     | -.27        |
| Other              | 4.2                  | 83                  | .09     | -.88        |

Abbreviation: CC, Coefficient of correlation.

aBased on the defined cutoff (3.4 mg/dL).

*Significant at 0.05.
the OS, we further illustrated the median of UA in each disease and evaluate the correlation between UA level and OS in each category. As it is reported in the result, the only disease in which the UA and OS is significantly correlated with AML which is accordant with the better OS of AML patients seen in the Cox regression model. The other diseases had no better OS and also no correlation of UA and OS. Interestingly, among the diseases, the nearest median UA level to the cutoff (3.4 mg/dL) is for AML patients and almost half of the AML patients is hyperuricemic. The correlation of UA level and OS in AML patients is negative showing higher UA level correlates with poor OS which is in line with previous studies. The better OS of AML patients in our study was found only in univariable model while after adjusting with other covariates including UA, this better OS is not significant anymore.

Conclusively, we demonstrated that the lower serum UA levels are associated with GVHD incidence and inferior overall survival. Our result is in line with some previous studies and contradicts some others which suggest that there might be an optimum range for UA levels which control the HSCT outcome and UA levels either lower or higher than this range could be detrimental for HSCT outcome. More comprehensive studies can evaluate the validity of this hypothesis.

ACKNOWLEDGMENT

The authors would like to thank of Hematopoietic Stem Cell Research Center and Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran for providing the possibility of doing the study and helpful assistance.

AUTHOR CONTRIBUTIONS

K.GH, SP, SS, and AH participated in designed experiments and critical revision of the manuscript; RN, MHK, and M.S performed data collection and analyzed the data. All authors revised the manuscript and approved the final paper.

ORCID

Abbas Hajifathali https://orcid.org/0000-0002-2711-9277

REFERENCES

1. Aljurf M, Weisdorf D, Alfraih F. et al. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries. Bone Marrow Transplant. 2019;54(8):1179-1188.

2. Chao NJ. Clinical Manifestations, Diagnosis and Grading of Acute Graft-versus-Host Disease. UpToDate: Waltham, MA; 2017:30.

3. Jagasia M, Arora M, Flowers ME. et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119(1):296-307.

4. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443.

5. Filipovich AH, Weisdorf D, Pavletic S. et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.

6. Jacobsbohn DA, Arora M, Klein JP. et al. Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. Blood. 2011;118(16):4472-4479.

7. Cannell P, Herrmann R. Urate metabolism during bone marrow transplantation. Bone Marrow Transplant. 1992;10(4):337-339.

8. Mirza N, Prokop L, Kowalewski D. et al. Soluble heat shock protein 70 members in patients undergoing allogeneic hematopoietic cell transplantation. Transpl Immunol. 2016;36:25-31.

9. Ryckman C, McColl SR, Vandal K. et al. Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis. Arthritis Rheum. 2003;48(8):2310-2320.

10. Hu D-E, Moore AM, Thomsen LN. Brindle KM. Uric acid promotes tumor immune rejection. Cancer Res. 2004;64(15):5059-5062.

11. Busso N, So A. Microcrystals as DAMPs and their role in joint inflammation. Arthritis Rheumatol. 2012;51(7):1154-1160.

12. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425(6957):516.

13. Socié G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood. 2009;114(20):4327-4336.

14. Ostendorf BN, Blau O, Uharek L, Blau IW, Penack O. Association between low uric acid levels and acute graft-versus-host disease. Ann Hematol. 2015;94(1):139-144.

15. Haen SP, Eyb V, Mirza N, et al. Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies. J Cancer Res Clin Oncol. 2017;143(5):759-771.

16. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.

17. Wilhelm K, Ganesan J, Müller T, et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7 R. Nat Med. 2010;16(12):1434.

18. Zeiser R, Penack O, Holler E, Izdko M. Danger signals activating innate immunity in graft-versus-host disease. J Mol Med. 2011;89(9):833.

19. Jankovic D, Ganesan J, Bscheider M, et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med. 2013;210(10):1899-1910.

20. Martinon F, Párrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237.

21. Eleftheriadis T, Pissas G, Soundakis M, et al. Uric acid increases cellular and humoral alloimmunity in primary human peripheral blood mononuclear cells. Nephrol. 2018;23(7):610-615.

22. Yeh AC, Brunner AM, Spitzer TR, et al. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(5):730-734.

23. Müller E, Hübner M, Kuderer S, et al. Effect of the preventative allopurinol therapy within the framework of the peripheral blood stem cell donation. J Cell Biotechnol. 2018;3(2):117-125.

24. Abraham A, Drory VE. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol. 2014;261(6):1133-1138.

25. Auinger P, Kieburgt K, Mc Dermott MP. The relationship between uric acid levels and Huntington’s disease progression. Mov Disorder. 2010;25(2):224-228.

26. Cankurtaran M, Yesil Y, Kuyumcu ME, et al. Altered levels of homocysteine and serum natural antioxidants links oxidative damage to Alzheimer’s disease. J Alzheimer’s Dis. 2013;33(4):1051-1058.
27. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42.

28. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant-and radi cal-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78(11):6858-6862.

29. Azar Y, Shainer R, Almogi-Hazan O, et al. Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model). Biol Blood and Marrow Transplant. 2013;19(4):519-528.

30. Suh JH, Kanathethath B, Shenvi S, et al. Thiol/redox metabolomic profiling implicates GSH dysregulation in early experimental graft versus host disease (GVHD). PloS One. 2014;9(2):e88868.

31. Bakhshaei P, Kazemi MH, Golara M, et al. Investigation of the cellular immune response to recombinant fragments of filamentous hemagglutinin and pertactin of bordetella pertussis in BALB/c mice. J Interferon Cytokine Res. 2018;38(4):161-170.

32. Inai K, Tsutani H, Ueda T. Hyperuricemia associated with hematological malignancies. Gout Nucleic Acid Metab. 1999;23:181-186.

33. Tsimberidou A-M, Kantarjian HM, Wen S, et al. The prognostic significance of serum β2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clin Cancer Res. 2008;14(3):721-730.

34. Yamauchi T, Negoro E, Lee S, et al. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res. 2013;33(9):3947-3951.

How to cite this article: Ghasemi K, Parkhideh S, Kazemi MH, et al. The role of serum uric acid in the prediction of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. J Clin Lab Anal. 2020;34:e23271. https://doi.org/10.1002/jcla.23271